Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model.

Immune responses against adenoviral vectors may influence the toxicity and therapeutic effectiveness of adenovirus-mediated gene transfer and may be a limiting factor in adenovirus-mediated gene therapy. The purpose of this study was to determine the effects of preimmunization on intratumoral adenoviral transduction and systemic spread. The hypothesis was that increased doses of adenoviral vectors could overcome local neutralization without added systemic toxicity. The level and duration of gene expression were assessed as a function of time and dose after intratumoral delivery of adenoviral vector (AdV) encoding the luciferase reporter gene (AdV-luc) in a subcutaneous mouse mammary tumor model. Preimmunization resulted in significantly decreased gene expression in tumor and normal tissues (P < 0.01). The decrease was significantly greater in liver than in tumor. Increased AdV doses could be used to overcome the intratumoral inhibition without a concomitant increase in liver transduction. However, preimmunized animals showed greater toxicity than nai;ve animals (P < 0.001). The preimmunized group developed histologic evidence of grade 2-3 hepatic toxicity and increases in the average values of hepatic enzymes. In addition, there was a significant increase in mortality (P < 0.01) in the preimmunized group (12 of 20 animals) compared with the naive group (3 of 20 animals). These findings suggest that although preimmunity can inhibit systemic expression from adenoviral vectors, at high vector doses it may potentiate hepatotoxicity.

[1]  E. Furth,et al.  A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. , 2002, Human gene therapy.

[2]  W. F. Anderson.  Assessment of adenoviral vector safety and toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee , 2002 .

[3]  A. Beaudet,et al.  Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. , 2002, Human gene therapy.

[4]  R. Burger,et al.  Complement activation by recombinant adenoviruses , 2001, Gene Therapy.

[5]  E. B. Butler,et al.  Enhanced therapeutic effect of multiple injections of HSV-TK + GCV gene therapy in combination with ionizing radiation in a mouse mammary tumor model. , 2001, International journal of radiation oncology, biology, physics.

[6]  T. Wheeler,et al.  Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. , 2001, Human gene therapy.

[7]  E. B. Butler,et al.  Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer--a preliminary report. , 2001, International journal of radiation oncology, biology, physics.

[8]  B. Ludviksson,et al.  The effect of TGF‐β1 on immune responses of naïve versus memory CD4+ Th1/Th2 T cells , 2000, European journal of immunology.

[9]  P. Scardino,et al.  Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer. , 2000, The Journal of urology.

[10]  A. Beaudet,et al.  Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Scardino,et al.  In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. , 1999, Human gene therapy.

[12]  J. Wilson,et al.  Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. , 1999, Human gene therapy.

[13]  T. Thompson.  In situ gene therapy for prostate cancer. , 1999, Oncology research.

[14]  James M. Wilson,et al.  Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.

[15]  J. Gauldie,et al.  Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination , 1997, Gene Therapy.

[16]  A. Beaudet,et al.  Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. , 1997, Human gene therapy.

[17]  P. Shabram,et al.  Sensitivity and reproducibility in adenoviral infectious titer determination , 1997, Nature Medicine.

[18]  J. Wilson,et al.  Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. , 1996, Gene therapy.

[19]  M. Kay,et al.  Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. , 1995, Human gene therapy.

[20]  B. Trapnell.  Adenoviral vectors for gene transfer , 1993 .

[21]  L. Whetter,et al.  Immune-mediated thrombocytopenia in horses infected with equine infectious anemia virus , 1991, Journal of virology.

[22]  M. Zern,et al.  Two rat models of hepatic fibrosis. A morphologic and molecular comparison. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[23]  H. Riccomi,et al.  The occurrence of circulating immune complexes and viral antigens in idiopathic thrombocytopenic purpura. , 1977, Clinical and experimental immunology.